Priscilla Ching
Family · San Antonio, TXNPI 1487315263
Payments from drug & device makers
Across 598 payments — averaging $20.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- Corcept Therapeutics$1K
- Novo Nordisk$985
- Cequr Corporation$836
- Dexcom, Inc.$832
- Sequel Med Tech, LLC$777
- plus $6K from 27 others
What the payments were for
- Travel & lodging$2302%
- Food & beverage$12,15197%
- Education$851%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 68 | $1,572 |
| Corcept Therapeutics | 59 | $1,073 |
| Novo Nordisk | 45 | $985 |
| Cequr Corporation | 3 | $836 |
| Dexcom, Inc. | 38 | $832 |
| Sequel Med Tech, LLC | 45 | $777 |
| Boehringer Ingelheim | 40 | $759 |
| Novartis | 61 | $678 |
| Medtronic | 8 | $663 |
| Xeris Pharmaceuticals, Inc. | 36 | $623 |
| Ascensia Diabetes Care US Inc. | 37 | $529 |
| Mannkind Corporation | 33 | $377 |
| AstraZeneca(2 entities) | 7 | $323 |
| Recordati_rare_diseases_inc. | 18 | $308 |
| Amgen | 18 | $279 |
| Kyowa Kirin, Inc. | 12 | $273 |
| Radius Health, Inc. | 15 | $259 |
| Bayer | 14 | $227 |
| Tandem Diabetes Care, Inc. | 6 | $217 |
| Madrigal Pharmaceuticals | 5 | $205 |
| BETA Bionics, Inc. | 5 | $188 |
| Insulet Corporation | 8 | $133 |
| Soleno Therapeutics, Inc. | 3 | $82 |
| AbbVie | 3 | $49 |
| Averitas Pharma Inc. | 2 | $34 |
| Rhythm Pharmaceuticals, Inc. | 1 | $32 |
| Pfizer | 2 | $28 |
| Tolmar, Inc. | 1 | $24 |
| Almatica Pharma LLC | 1 | $22 |
| Chiesi USA, Inc. | 1 | $22 |
| GSK | 1 | $21 |
| Ascendis Pharma Endocrinology Inc | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$836
- MINIMED 780G$420
- iLet Bionic Pancreas$354
- DEXCOM G6 TRANSMITTER$293
- TWIIST$284
- ZEPBOUND$247
- Korlym$220
- LOKELMA$125
- MOUNJARO$125
- t:slim X2 Insulin Pump with Control-IQ$121
- REZDIFFRA$113
How this compares
$12,466 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RecorlevLevoketoconazole | 11 | $257,301 |
| MounjaroTirzepatide | 177 | $208,914 |
| OzempicSemaglutide | 152 | $188,473 |
| JardianceEmpagliflozin | 65 | $64,573 |
| TrulicityDulaglutide | 57 | $59,183 |
| Cequr SimplicityBolus Insulin Pump, 200 Unit | 47 | $40,953 |
| AfrezzaInsulin Regular, Human | 12 | $30,534 |
| FarxigaDapagliflozin Propanediol | 20 | $28,616 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 26 | $24,660 |
| ProliaDenosumab | 14 | $23,235 |
| Tresiba Flextouch U-100Insulin Degludec | 32 | $22,961 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 17 | $17,752 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 18 | $16,453 |
| FiaspInsulin Aspart (Niacinamide) | 15 | $15,321 |
| LyumjevInsulin Lispro-Aabc | 20 | $15,034 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog, Baqsimi | $1,572 | $295,513308 claims |
| Xeris Pharmaceuticals, Inc.Recorlev | $623 | $257,30111 claims |
| Novo NordiskOzempic, Fiasp, Novolog | $985 | $207,352181 claims |
| Boehringer IngelheimJardiance | $759 | $64,57365 claims |
| Cequr CorporationCequr Simplicity | $836 | $40,95347 claims |
| Mannkind CorporationAfrezza | $377 | $30,53412 claims |
| AstraZenecaFarxiga | $323 | $28,61620 claims |
| AmgenProlia | $279 | $23,23514 claims |
| AbbVieSynthroid | $49 | $2,81030 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in San Antonio
- Anna CastroSan Antonio$184K
- Natalia FariasSan Antonio$124K
- Ayoade AvworoSan Antonio$111K
- Tina CoppleSan Antonio$97K
- Kim HinojosaSan Antonio$63K
- Kimberly GibergaSan Antonio$36K
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.